^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Waldenstrom Macroglobulinemia |
| Drug: | Rituxan (rituximab) (CD20 inhibitor) + bortezomib (Proteasome inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Waldenstrom’s Macroglobulinaemia/Lymphoplasmacytic Lymphoma: Other recommended regimens…Bortezomib ± rituximab
